Quantum-Si Inc. 10-Q Summary: Q3 2024
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Quantum-Si Inc. is a life sciences company developing a proprietary single-molecule detection platform for Next-Generation Protein Sequencing (NGPS). The company's primary commercial product is the Platinum® NGPS instrument, which underwent a full commercial launch in Q1 2024. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $787 | $223 | $1,866 | $682 |
| Gross Profit | $367 | $108 | $990 | $310 |
| Gross Margin | 46.6% | 48.4% | 53.1% | 45.5% |
| Net Loss | $(25,313) | $(24,728) | $(67,886) | $(73,912) |
| Operating Cash Flow | N/A | N/A | $(64,914) | $(73,067) |
| Cash & Marketable Securities | $196,344 | N/A | N/A | N/A |
| Accumulated Deficit | $(563,520) | N/A | N/A | N/A |
Note: Cash and Marketable Securities as of Sept 30, 2024, totaled $196.3 million ($42.3M cash + $154.1M securities). No long-term debt is reported.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 253% year-over-year for Q3 and 174% for the nine-month period, driven by the full commercial launch of the Platinum® instrument and increased sales of consumables.
- Expense Management: Research and Development (R&D) expenses decreased 16% for the nine months ended Sept 30, 2024, compared to the prior year, primarily due to reduced payroll costs from 2023 restructuring and lower fabrication costs. However, this was partially offset by a $2.4 million inventory write-down.
- SG&A Increase: Selling, General, and Administrative expenses increased 10% for the nine-month period, driven by investments in commercial operations and higher stock-based compensation.
- Investment Income: Dividend and interest income increased significantly (26% for nine months) due to higher yields on marketable securities. Unlike the prior year, there were no unrealized gains or realized losses on trading securities in 2024.
Outlook, Risks, and Contingencies
- Liquidity: Management believes current cash and marketable securities ($196.3M) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring negative operating cash flows until revenue scales.
- Nasdaq Compliance Risk: On November 4, 2024, the company received a notice from Nasdaq stating its stock price had closed below $1.00 for 30 consecutive days. The company has until May 5, 2025, to regain compliance or risk delisting.
- Legal Proceedings:
- Stockholder Litigation: A class action lawsuit filed in May 2024 alleges breach of fiduciary duty regarding the 2021 business combination. The outcome is currently not estimable.
- Contract Manufacturer Dispute: A former contract manufacturer filed a breach of contract claim in Minnesota; the company intends to vigorously defend the claim.
- Lease Dispute: Ongoing litigation regarding $9.1 million in lease incentives for the New Haven facility.
- Guidance: The filing does not provide specific numerical financial guidance for future periods.
Key Facts for Investor Verification
- Delisting Risk: Verify the company's plan to regain Nasdaq compliance (stock price >$1.00) by May 5, 2025.
- Inventory Valuation: Confirm the rationale and magnitude of the $2.4 million inventory write-down recorded in R&D expenses.
- Revenue Sustainability: Assess whether the 253% revenue growth in Q3 is sustainable or driven by one-time instrument shipments.
- Cash Burn Rate: Monitor the net cash used in operating activities ($64.9M for nine months) against the $196.3M cash runway.
- Legal Exposure: Track the status of the Delaware Stockholder Litigation and the contract manufacturer dispute for potential financial impact.